logo-loader
Pharmaxis Ltd

Director/PDMR Shareholding

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .z{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 42.55pt 2.0cm;}div.z{}p.az{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";}p.ba{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.av{color:black}p.bb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.au{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.bc{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}table.bd{width:486.85pt;margin-left:-10.8pt;border-collapse:collapse} td.ar{width:10.85pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aq{width:454.4pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ap{width:10.85pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:138.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.an{width:305.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.am{width:454.4pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.be{width:245.75pt;border-collapse:collapse;border:none}tr.ai{height:27.25pt}td.ak{width:92.7pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}span.al{color:black;border:none windowtext 1.0pt; padding:0cm} td.aj{width:131.45pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ah{width:92.7pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ag{width:131.45pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}table.bf{margin-left:-5.4pt;border-collapse:collapse}td.ac{width:214.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.ad{font-size:11.0pt}span.bg{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;font-family:"Calibri","sans-serif"} /**/
RNS Number : 1765M
Provexis PLC
12 September 2019
 

12 September 2019

 

Provexis plc

 

("Provexis" or the "Company")

 

Director / PDMR notification

 

 

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.

 

Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford

 

2

 

Reason for the notification

a)

 

Position/status

 

See 1a) above

 

b)

 

Initial notification

/ Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

PROVEXIS PLC

b)

 

LEI

 

21380042E3Y3N9VZ6N48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 0.1p each

 

 

 

ISIN: GB00B0923P27

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

 

 

 

 Price(s)

Volume(s)

0.33 pence

and

0.345 pence

2,500,000

 

2,500,000

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

5,000,000 shares

 

Average price of 0.338 pence per share

 

e)

 

Date of the transaction

 

12 September 2019

f)

 

Place of the transaction

 

London Stock Exchange, AIM Market

 

 

For further information please contact:

 

Provexis plc

Dawson Buck, Chairman

Ian Ford, CEO & CFO

 

Tel:         07490 391888

                [email protected]

Allenby Capital Limited

Nick Naylor / Liz Kirchner

Tel:         020 3328 5656

 

 

 

Notes for editors

 

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

 

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

 

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

 

For further information, please visit www.provexis.com and www.fruitflowplus.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGGUQGBUPBGCP

Quick facts: Pharmaxis Ltd

Price: 0.21

Market: ASX
Market Cap: $82.88 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19